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Abstract 
Zolendronic acid is a potent bisphosphonate that is used 
to treat patients with metastatic cancer by reducing bone 
pain and preventing skeletal complications of bone 
metastasis.   
We reported the case of a lady suffering from 
metastatic breast cancer who developed seizures secondary 
to severe hypocalcaemia after being treated with 
Zolendronic acid.  Hypocalcaemia was unresponsive to 
treatment until vitamin D and magnesium deficiencies 
were corrected.  This case highlights the importance of 
taking serum magnesium and vitamin D levels in patients 
presenting with resistant hypocalcaemia following 
bisphosphonate administration, especially in those with 
underlying bone malignancy. 
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Case report 
A 70 year old Caucasian woman was referred to 
Karen Grech Rehabilitation Hospital for rehabilitation 
after sustaining a pathological fracture in the left 
femur in January 2010.  She was diagnosed with breast 
carcinoma in 2005 and was treated with surgery and 
radiotherapy.  She developed a pathological fracture of 
the lumbar vertebrae in January 2009 which was 
treated by surgical fixation followed by radiotherapy.  
She was later started on regular disodium Pamidronate 
90mg every 6 weeks.  She then spent 12 months in 
overall good health at home but presented with a 
pathological fracture of her left femur.  This was 
managed by surgical fixation.  A bone scan taken at 
the time showed multiple bone metastasis.  According 
to current recommendations, disodium Pamidronate 
was changed to Zolendronic acid which was given at 
the standard dose of 4mg diluted in 100ml sterile 0.9% 
sodium chloride intravenously over one hour.  Prior to 
commencing Zolendronic acid the patient’s serum 
creatinine was 68umol/l (reference range 45-84) and 
the corrected serum calcium was 2.34 
mmol/l(reference range 2.15-2.55).   She was also on 
the recommended doses of calcium (600mg) and 
vitamin D (400IU) daily. 
 
Her condition deteriorated after being given the 
second dose of Zolendronic acid.  She complained of 
perioral tingling, parasthesia, developed tetany with a 
positive Trousseau`s sign and Chvostek`s sign and 
then sustained generalised tonic clonic seizures.  Her 
serology revealed hypocalcaemia with corrected 
calcium level of 1.35 mmol/l(reference range 2.15-
2.55).  Serum 25 (OH) vitamin D level was also taken 
and was later found to be low (<7 ng/ml; reference 
range 20 -70).  Multiple doses of 10cc of 10% 
intravenous calcium gluconate were initially 
administered, followed by concurrent administration 
of oral calcium carbonate tablets (3g daily) and 
alfacalcidol (0.25 microgram daily).  Hypocalcaemia 
was resistant to treatment even though treatment was 
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given for several days and the seizures worsened in 
frequency and severity.    
 
Further investigations revealed a concomitant 
hypomagnesemia with magnesium level of 0.25 
mmol/l(reference range 0.65-1.05).  This was corrected 
with several bolus of 4g intravenous magnesium sulphate 
(16g over 8 days).  Upon treating the hypocalcaemia and 
hypomagnesemia, the tetany and seizures subsided and the 
patient`s condition improved.   
 
  
Discussion 
Zolendronic acid is an intravenous bisphosphonate that 
suppresses the formation and function of osteoclasts.1  The 
majority of patients receiving bisphosphonates do not 
suffer from hypocalcaemia because of the compensatory 
mechanism of parathyroid hormone which induces renal 
reabsorption of calcium, increases vitamin D production 
and stimulates osteoclasts to resorb bone. In this case 
report hypocalcaemia was not corrected by the parathyroid 
hormone response because of the lack of vitamin D.   
 
This case and similar cases in literature highlight the 
need for avoiding bisphosphonate-induce hypocalcaemia 
by routine checking of renal function, calcium levels and 
vitamin D levels and adequate replacement prior to starting 
therapy.1-6   
 
In the setting of hypocalcaemia, hypomagnaesemia 
must not be overlooked.  The homeostasis of magnesium 
depends upon gastrointestinal absorption and renal 
excretion.  Most of the absorption of magnesium occurs in 
the ileum by two processes.  The principal route is across 
the transient receptor potential melastatin (TRPM6) 
channel.7-10  This channel is a bifunctional protein that 
combines both calcium and magnesium and actively 
transport them across the membrane.7,9,10     The second 
route through which magnesium is absorbed in the ilium  
is the paracellular route and this occurs passively.8  
Magnesium is mostly reabsorbed by the thick ascending 
loop of Henle (TAL) (60-70%) and only some magnesium 
is absorbed in the proximal and distal convoluted tubule.    
In the TAL, magnesium is passively absorbed with 
calcium via paracellular tight junctions known as 
paracelin-1.  The driving force behind this passive 
reabsorption  is the positive electrochemical gradient 
caused by reabsorption of sodium chloride.  Also in the 
basolateral membrane of the TAL there are Ca+/Mg+ -
sensing receptor.  These receptors sense both calcium and 
magnesium and when there is excess of either of these 
ions, they decrease magnesium absorption.8  In the 
distal convoluted tubule, magnesium is actively 
absorbed via the TRPM6 channel.
9,10
  Apart from the 
above, patients  who have hypomagnesemia have 
inappropriately low serum levels of  parathyroid 
hormone (PTH) and bone is resistant to the effect of 
PTH.7,8  The reason for this is still unknown but this 
low PTH level would further lower calcium levels.      
 
The above discussion highlights how the calcium, 
vitamin D and magnesium homeostatic mechanisms 
are closely interlinked and in the case presented 
hypocalcaemia was refractory to treatment until the 
concomitant hypomagnesemia and vitamin D 
deficiency were corrected.  
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